Search clinical trials for: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

Total 1657 results

University of Nebraska
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Lymphoma

United States
Acrotech Biopharma Inc.
Axis Clinicals Limited

Unknown

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Hematologic Diseases
Hoffmann-La Roche

Completed

A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma

Hong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
Huiqiang Huang

Recruiting

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | EBV-Positive DLBCL, Nos | ALK-Positive Anaplastic Large Cell Lymphoma | Follicular Lymphoma Grade IIIb

China
German High-Grade Non-Hodgkin's Lymphoma Study...

Completed

Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

Germany, Israel, Italy
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia...

Completed

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Fernando Cabanillas
Genzyme, a Sanofi Company

Completed

Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL (CHOP-R)

Lymphoma | Non Hodgkin's Lymphoma

Puerto Rico
Commissie Voor Klinisch Toegepast Onderzoek

Unknown

Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Lymphoma

Netherlands
Universität des Saarlandes

Completed

Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

Lymphoma
European Organisation for Research and Treatment...
NCIC Clinical Trials Group; Stichting Hemato-Oncologie voor Volwassenen Nederland and other collaborators

Completed

Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Lymphoma

France, Netherlands, United Kingdom, Australia, Canada, Norway, Poland, Belgium, Italy, New Zealand, Denmark, Egypt, Hungary, Portugal, Slovakia, Slovenia, South Africa, Sweden
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Lymphoma

United States
German CLL Study Group

Completed

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)

Chronic Lymphocytic Leukemia

Germany
Amgen

Unknown

Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Lymphoma

United States
Eli Lilly and Company

Completed

A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only

Lymphoma

United States
German High-Grade Non-Hodgkin's Lymphoma Study...

Completed

Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Lymphoma

Germany, Switzerland
German High-Grade Non-Hodgkin's Lymphoma Study...

Completed

Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Lymphoma

Germany, Israel
Ohio State University Comprehensive Cancer Center

Withdrawn

Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma

Lymphoma
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma

Lymphoma

United States
Hoag Memorial Hospital Presbyterian
Cancer Biotherapy Research Group

Withdrawn

Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

Lymphoma

United States
Swiss Group for Clinical Cancer Research

Completed

Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL

Leukemia

Switzerland
Pusan National University Hospital

Unknown

Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over

Diffuse Large B-cell Lymphoma
German High-Grade Non-Hodgkin's Lymphoma Study...

Completed

Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Lymphoma

Switzerland, Germany, Italy, Netherlands, Poland, Sweden, United Kingdom, France, Czechia
Swiss Group for Clinical Cancer Research

Completed

PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Lymphoma

Switzerland, Italy
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma

Lymphoma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma

Lymphoma
British Columbia Cancer Agency
National Cancer Institute (NCI)

Completed

Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Lymphoma

Canada, United States
Li Zhiming
Antengene Corporation

Recruiting

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

DLBCL Germinal Center B-Cell Type

China
Medstar Health Research Institute

Withdrawn

Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States, Puerto Rico
Centre Antoine Lacassagne

Completed

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Lymphoma

France
National Cancer Institute (NCI)

Completed

Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Lymphoma

United States, Australia, South Africa, Peru, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Large B Cell Lymphoma

United States
Seagen Inc.

Terminated

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Diffuse, Large B-Cell, Lymphoma | Follicular Lymphoma, Grade 3b | Transformed Lymphoma / DLBCL

United States, Puerto Rico
Weill Medical College of Cornell University
Celgene

Completed

Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

United States
Genmab
AbbVie

Recruiting

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, United Kingdom, Belgium, Denmark, Netherlands, Finland, Czechia, Sweden, Australia, Norway
University Hospital Southampton NHS Foundation...
Janssen-Cilag Ltd.

Completed

A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib (REMoDL-B)

Lymphoma, Large B-Cell, Diffuse

United Kingdom, Switzerland
Chipscreen Biosciences, Ltd.

Active, not recruiting

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL (DEB)

Diffuse Large B-cell Lymphoma

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

China
SWOG Cancer Research Network
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Cancer and...

Active, not recruiting

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Lymphoma

United States
Seagen Inc.

Terminated

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Lymphoma, Large B-cell, Diffuse | Lymphoma, B-cell

United States, Spain, Italy, Czechia, Poland
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Genentech, Inc.

Completed

Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma

Lymphoma

United States
French Innovative Leukemia Organisation

Unknown

GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma

Lymphoma
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

Lymphoma

United States
Institut Bergonié
National Cancer Institute, France

Completed

Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial (FRAIL-06)

Lymphoma

France
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Lymphoma

United States

3

Subscribe